SPHK1 and prostate cancer: Therefore, although ABC294640 is an SK2 selective inhibitor with no direct inhibitor effect against recombinant SK1 at concentrations as high as 100 μM [9], it is able to remove SK1a from prostate cancer cells via an indirect mechanism.